1,1,1,2,2,3,3-Heptafluor-hexan | 678-98-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1,1,1,2,2,3,3-Heptafluor-hexan
• 英文别名: 1,1,1,2,2,3,3-heptafluoro-hexane；1,1,1,2,2,3,3-Heptafluorohexane
• CAS: 678-98-8
• 化学式: C₆H₇F₇
• 分子量: 212.11
• InChiKey: XMEPUXUKDYDDDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4,4,5,6,6,6-八氟-2-己烯 在 乙醚 、 镍 作用下， 100.0 ℃ 、9.81 MPa 条件下， 生成 1,1,1,2,2,3,3-Heptafluor-hexan
  参考文献：
  名称：

  Fluorinated Paraffins

  摘要：

  DOI：

  10.1021/jo01093a022

文献信息

• SEMIFLUORINATED COMPOUNDS AND THEIR COMPOSITIONS
  申请人：NOVALIQ GMBH

  公开号：US20170087100A1

  公开（公告）日：2017-03-30

  The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

  本发明涉及半氟化合物组成物及其作为局部给药用药物治疗眼部疾病的用途。
• SEMIFLUORINATED COMPOUNDS
  申请人：NOVALIQ GMBH

  公开号：US20170087101A1

  公开（公告）日：2017-03-30

  The present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.

  本发明涉及某些半氟化合物及包含此类化合物的组合物。本发明进一步提供了将该化合物和组合物用作局部给药于眼部的药物的用途。
• Pharmaceutical composition comprising propofol
  申请人：Novaliq GmbH

  公开号：EP2332525A1

  公开（公告）日：2011-06-15

  The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.

  本发明提供了包含活性成分异丙酚的新型药物组合物。异丙酚最好溶解在至少一种半氟化烷烃中。这种组合物最好是液体或凝胶状，也可以选择加入其他辅料。它们可用作胶囊的填充材料、口腔或鼻腔喷雾剂，或用作肺部给药的气雾剂。它们尤其适用于异丙酚的经粘膜给药。
• Pharmaceutical composition for treatment of dry eye syndrome
  申请人：Novaliq GmbH

  公开号：EP2335735A1

  公开（公告）日：2011-06-22

  The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble drug substances with immunosuppressant activity. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.

  本发明提供了以半氟化烷烃为基础的用于治疗角结膜炎的新型药物组合物，半氟化烷烃可用作多种活性成分的载体。首选的活性成分包括具有免疫抑制活性的难溶于水的药物物质。这些组合物可局部进入眼部。本发明进一步提供了包含此类组合物的试剂盒。
• Liquid pharmaceutical compositions for the delivery of active ingredients
  申请人：Novaliq GmbH

  公开号：EP2444063A1

  公开（公告）日：2012-04-25

  The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions.

  本发明提供了基于半氟化烷烃的新型药物组合物，可用作多种活性成分的载体。首选的活性成分包括水溶性差和/或水解敏感的药物物质。这些组合物被设计成悬浮液，具有优异的物理性质，因此非常适合用作给药系统。本发明的组合物可通过局部给药进入眼部，也可通过皮下或肌内途径进行注射。本发明进一步提供了包含此类组合物的试剂盒。